Advances in Targeted At-211 Alpha Therapy
A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Chemical Biology".
Deadline for manuscript submissions: 30 September 2026 | Viewed by 44
Special Issue Editors
Interests: radiology; neurodegenerative disease; positron emission tomography (PET); oxidative stress; neuroinflammation
Special Issue Information
Dear Colleagues,
Astatine-211 (211At), an alpha-emitting radionuclide, has emerged as a promising isotope for targeted radiotherapy, offering potent and localized cytotoxicity against disseminated cancers. Over the past decade, remarkable progress has been achieved in 211At production, target processing, and isolation technologies, as well as in the development of robust radiolabeling strategies that improve stability and in vivo performance.
This Special Issue will showcase advances spanning the entire field of 211At research—from targetry, chemistry (separation and radiolabeling), and automation to innovative labeling strategies. In addition, the development and evaluation of astatinated biomolecules (small molecule, peptide, or antibody), and studies elucidating biological mechanisms of action, dosimetry, and other research aimed at advancing the translation of 211At to the clinic will also be discussed in this issue. Together, these developments are shaping the foundation for clinical translation and expanding the therapeutic reach of alpha-emitting radionuclides.
In this Special Issue of Biomolecules, we invite original research articles, comprehensive reviews, and perspective papers focusing on innovations in 211At chemistry, biology, and radiopharmaceutical applications. By gathering recent insights and technological breakthroughs, this collection aims to accelerate progress toward the safe, reliable, and widespread use of 211At in targeted alpha therapy.
Dr. Hsiaoju Sharon Lee
Dr. Yawen Li
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Astatine-211
- astatination
- targeted alpha therapy
- alpha radioimmunotherapy
- radiotheranostics
- radiopharmaceuticals
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
